Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Marcucci

Showing results (341-350 of 536) with videos related to

Pageof 54
Sort By:
Blood|August 22, 2008
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Manuela Hummel, Clara D Bloomfield, et al.
Cancer Research|May 17, 2020
State-Transition Analysis of Time-Sequential Gene Expression Identifies Critical Points That Predict Development of Acute Myeloid LeukemiaRussell C Rockne, Sergio Branciamore, Jing Qi, et al.
Bone Marrow Transplantation|November 8, 2019
Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosisRohan Gupta, Faizi Jamal, Dongyun Yang, et al.
Transplantation and Cellular Therapy|March 30, 2021
Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage TherapiesIbrahim Aldoss, Dongyun Yang, Monzr M Al Malki, et al.
American Journal of Hematology|August 11, 2020
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromeCaner Saygin, Karilyn Larkin, James S Blachly, et al.
The Journal of Clinical Investigation|December 17, 2013
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activityChinavenmeni S Velu, Aditya Chaubey, James D Phelan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2010
Dose escalation of lenalidomide in relapsed or refractory acute leukemiasWilliam Blum, Rebecca B Klisovic, Heiko Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Bo Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2005
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activityGuido Marcucci, Wendy Stock, Guowei Dai, et al.
Blood|October 7, 2004
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemiaJohn C Byrd, Guido Marcucci, Mark R Parthun, et al.
Pageof 54

Showing results (341-350 of 536) with videos related to

Sort By:
Pageof 54
Blood|August 22, 2008
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Manuela Hummel, Clara D Bloomfield, et al.
Cancer Research|May 17, 2020
State-Transition Analysis of Time-Sequential Gene Expression Identifies Critical Points That Predict Development of Acute Myeloid LeukemiaRussell C Rockne, Sergio Branciamore, Jing Qi, et al.
Bone Marrow Transplantation|November 8, 2019
Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosisRohan Gupta, Faizi Jamal, Dongyun Yang, et al.
Transplantation and Cellular Therapy|March 30, 2021
Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage TherapiesIbrahim Aldoss, Dongyun Yang, Monzr M Al Malki, et al.
American Journal of Hematology|August 11, 2020
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromeCaner Saygin, Karilyn Larkin, James S Blachly, et al.
The Journal of Clinical Investigation|December 17, 2013
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activityChinavenmeni S Velu, Aditya Chaubey, James D Phelan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2010
Dose escalation of lenalidomide in relapsed or refractory acute leukemiasWilliam Blum, Rebecca B Klisovic, Heiko Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Bo Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2005
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activityGuido Marcucci, Wendy Stock, Guowei Dai, et al.
Blood|October 7, 2004
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemiaJohn C Byrd, Guido Marcucci, Mark R Parthun, et al.
Pageof 54